Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Alkem Laboratories Limited, is an unlisted public company incorporated on 08 August, 1973. It is classified as a public limited company and is located in Mumbai, Maharashtra. It's authorized share capital is INR 50.00 cr and the total paid-up capital is INR 23.91 cr.
Alkem Laboratories Limited's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2023. It's EBITDA has decreased by 23.94% over the previous year. At the same time, it's book networth has increased by 6.93%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
2.55%
-23.94%
-26.39%
6.93%
-49.86%
-3.33%
-1.93
-5.29
-4.9
-5.5
-12.97
-0.14
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(94)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
CitiBank N.A.
No. of Loans: 1
Total Amount : 342.0 cr
HDFC Bank Limited
No. of Loans: 1
Total Amount : 270.3 cr
Kotak Mahindra Bank Limited
No. of Loans: 2
Total Amount : 180.0 cr
ICICI Bank Limited
No. of Loans: 1
Total Amount : 108.0 cr
State Bank of India
No. of Loans: 2
Total Amount : 100.2 cr
Bank of India
No. of Loans: 1
Total Amount : 85.0 cr
MEMBER SECRETARY SINGLE WINDOW CLEARANCE AGENCY
No. of Loans: 1
Total Amount : 0.3 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| CS | Manish Narang
Shareholder
|
<HIDDEN> | 18 years |
| Director | Arun Kumar Purwar | 00026383 | 10 years |
| Director | Narendra Aneja | 00124302 | 5 years |
| Whole-time Director | Basudeo Narayan Singh
Shareholder
|
00760310 | 51 years |
| Whole-time Director | Mritunjay Kumar Singh
Shareholder
|
00881412 | 17 years |
| Director | Rajeev Kher | 01192524 | 0 years |
| Managing Director | Sandeep Singh
Shareholder
|
01277984 | 11 years |
| Whole-time Director | Sarvesh Singh
Shareholder
|
01278229 | 5 years |
| Director | Sujjain Suresh Talwar | 01756539 | 2 years |
| Whole-time Director | Srinivas Balmiki Prasad Singh
Shareholder
|
06744441 | 2 years |
| Director | Sudha Ravi | 06764496 | 9 years |
| Director | Sangeeta Kapil Jit Singh | 06920906 | 9 years |
| Kmp | Nitin Agrawal | <HIDDEN> | 1 years |
| Whole-time Director | Madhurima Singh
Shareholder
|
09137323 | 3 years |
| Kmp | Vikas Gupta | <HIDDEN> | 1 years |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Ascend Laboratories SDN BHD | Malaysia | - | - |
| S & B Holdings B.V | Netherlands | - | - |
| Pharmacor Limited | New Zealand | - | - |
| Alkem Laboratories Corporation | Philippines | - | - |
| Ascend Laboratories (Pty) Limited | South Africa | - | - |
| ThePharmaNetwork, LLC | United States | - | - |
| Ascend Laboratories LLC | United States | - | - |
| Ascend Laboratories (UK) Limited | United Kingdom | - | - |
| ALKEM FOUNDATION | Maharashtra | 2010 | ₹ 1.0 L |
| Pharmacor Pty Limited | Australia | - | - |
| Ascend Laboratories Limited | Canada | - | - |
| Pharma Network SpA | Chile | - | - |
| Ascend Laboratories SAS | Colombia | - | - |
| CONNECT 2 CLINIC PRIVATE LIMITED | Maharashtra | 2020 | ₹ 1.5 Cr |
| S&B Pharma LLC | United States | - | - |
| CACHET PHARMACEUTICALS PRIVATE LIMITED | Bihar | 1978 | ₹ 17.8 L |
| Ascend Laboratories SpA | Chile | - | - |
| ENZENE BIOSCIENCES LIMITED | Maharashtra | 2006 | ₹ 51.3 Cr |
| Ascend GmbH | Germany | - | - |
| INDCHEMIE HEALTH SPECIALITIES PRIVATE LIMITED | Maharashtra | 1986 | ₹ 25.0 L |
| The PharmaNetwork, LLP | Kazakhstan | - | - |
| Alkem Laboratories Korea Inc | Korea, Republic Of | - | - |
| Ascend Laboratories S.A. DE C.V. | Mexico | - | - |
| Enzene Inc | United States | - | - |
| Ascend Laboratories (Pty) Limited (formerly known as Alkem Laboratories (Pty) Limited) | South Africa | - | - |
| Ascend GmbH (Formerly known as Alkem Pharma GmbH) | Germany | - | - |
| Ascend Laboratories S.A. DE C.V | Mexico | - | - |
The incorporation date of ALKEM LABORATORIES LIMITED is 08 August, 1973
The authorized share capital of ALKEM LABORATORIES LIMITED is INR ₹ 50.0 Cr.
The paid-up capital of ALKEM LABORATORIES LIMITED is INR ₹ 23.9 Cr.
The registered address of ALKEM LABORATORIES LIMITED is ALKEM HOUSE, SENAPATI BAPAT MARG LOWER PAREL MUMBAI Maharashtra - 400013
The CIN number of ALKEM LABORATORIES LIMITED is L00305MH1973PLC174201.
Expand
Delete
Collapse
See
details
It will take sometime. Please come back in 10
minutes
